A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities

What Was Tested

In this phase 1 trial, researchers set out to test VK2735.

It had 18 arms (groups): Placebo (placebo comparator), one (experimental), one (experimental), one (experimental) and one (experimental).

Placebo Subcutaneously (SC) weekly.

VK2735 subcutaneously weekly followed by Placebo subcutaneously weekly.

VK2735 subcutaneously weekly followed by VK2735 subcutaneously weekly.

The registry classes the interventions as drug.

More on the Plan

Approximately 270 participants will be enrolled across two study parts: Part A and Part B.

A total of 18 treatment groups are planned.

Part A contains Groups 1 to 12, and Part B contains Groups 13 to 18.

Part A will be completed prior to the enrollment of Part B.

Who Took Part

The registry lists 270 planned participants were the target.

It was open to people of any sex aged from 18 years up to 60 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Must be capable of giving a signed informed consent form (ICF). BMI ≥ 30 kg/m2. Willing to comply with contraceptive requirements.

The full record lists 4 inclusion and 8 exclusion criteria; among the exclusions: participants with any level of disease or organ system dysfunction as identified during physical examination, medical history, or laboratory testing, as assessed by the investigator; any surgical or medical condition (active or chronic) that may interfere with ip distribution, metabolism, excretion or drug absorption; current or past diagnosis of diabetes mellitus (including type 1 and type 2, except gestational diabetes).

How the Study Was Run

The set-up was randomized, parallel-group and double-blind.

Because people in this VK2735 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

As a double-blind VK2735 study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant and investigator.

It started in 2025-11-18 with completion listed for 2027-05.

It ran at 2 sites in United States (2).

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Evaluate the Safety and Tolerability VK2735 (time frame: 33 weeks).

What This Means in Plain Language

Put simply, this is a phase 1, randomized trial of VK2735 in 270 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the VK2735 compound page, all human trials.